
Amgen Patents

Matching "Amgen" by Owner.

IPMonitor
Patents

Contents

| | |
|--|----|
| Alerts | 3 |
| "Amgen" | 3 |
| Terms and Conditions | 20 |
| General | 20 |
| Disclaimer of warranty and limitation of liability | 20 |
| Copyright | 20 |
| Arbitration | 20 |

Alerts

"Amgen"

More than 500 results matching "Amgen" by Owner.

| Number | Title | Owner |
|----------------------------|---|----------------------------------|
| 2002300154 | Stem Cell Factor | Amgen Inc. |
| 2002303091 | G-protein coupled receptor molecules and uses thereof | Amgen, Inc. |
| 2002303880 | Tumor endothelial marker 7a molecules and uses thereof | AMGEN, INC. |
| 2002305168 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. |
| 2001297717 | CXCR3 antagonists | Amgen SF, LLC |
| 2002311891 | SERINE THREONINE KINASE MEMBER, h2520-40 | AMGEN, INC. |
| 2002320157 | Antibodies to OPGL | Amgen Inc. ; Amgen Fremont Inc. |
| 2001297848 | ATP-BINDING CASSETTE TRANSPORTER-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. |
| 2002326469 | Substituted piperazines as modulators of the melanocortin receptor | Amgen Inc. |
| 2002329826 | 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer | Amgen Inc. |
| 2002329947 | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations | KIRIN-AMGEN, INC. |
| 2002330074 | TALL-1 RECEPTOR MOLECULES AND USES THEREOF | AMGEN INC. |
| 2002248339 | Substituted Arylamine Derivatives and Methods of Use | Amgen Inc. |
| 2002300605 | Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods | Amgen Inc. |
| 2002300970 | Novel DKR polypeptides | Amgen Inc. |
| 2002335796 | TUMOR ENDOTHELIAL MARKER 5Alpha MOLECULES AND USES THEREOF | AMGEN INC |
| 2002336390 | 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents | Amgen Inc. |
| 2002336532 | Linked biaryl compounds | Japan Tobacco, Inc. ; Amgen, Inc |
| 2002248340 | Substituted alkylamine derivates and methods of use | Amgen Inc. |
| 2002342669 | Peptides and related molecules that bind to TALL-1 | Amgen, Inc. |
| 2002338645 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. |
| 2002340176 | Peptides and related compounds having thrombopoietic activity | AMGEN INC. |
| 2002343498 | Angiopoietin-2 specific binding agents | Amgen Inc. |
| 2001251082 | CD20/IgE-receptor like molecules and uses thereof | Amgen Inc. |
| 2002253890 | Substituted Amine Derivatives and Methods of Use | Amgen Inc. |
| 2002348263 | Transgenic animals bearing human IgLamda light chain genes | Amgen Fremont Inc. |

| Number | Title | Owner |
|----------------------------|--|--|
| 2003200609 | Biodegradable sustained-release alginate gels | Amgen Inc. |
| 2002347978 | Fully human antibody fab fragments with human interferon-gamma neutralizing activity | Amgen Inc. |
| 2002352722 | Substituted indolizine-like compounds and methods of use | Amgen Inc. |
| 2002359288 | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment | Board of Regents, The University of Texas System ; Amgen, Inc. ; The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, of the United States Government |
| 2002359391 | MODULATORS OF RECEPTORS FOR PARATHYROID HORMONE AND PARATHYROID HORMONE-RELATED PROTEIN | AMGEN, INC. |
| 2003201360 | Methods of Reducing or Maintaining Reduced Levels of Blood Lipids Using OB Protein Compositions | Amgen Inc. |
| 2002359802 | Novel G-protein coupled receptors | Amgen Inc. |
| 2002361885 | Methods for using anti-MUC18 antibodies | Amgen fremont Inc. |
| 2003203048 | METHODS OF REGULATING CYTOKINE RECEPTOR SIGNALING | AMGEN INC. |
| 2002257329 | B7 RELATED PROTEIN-2 MOLECULES AND USES THEREOF | AMGEN, INC. |
| 2003203661 | Mammals Lacking Expression of Osteoprotegerin | Amgen Inc. |
| 2003204063 | Methods of increasing sensitivity of an individual to Ob protein by upregulating Ob protein receptor | Amgen Inc. |
| 2003204051 | OB Protein compositions and method | Amgen Inc. |
| 2003204238 | G-CSF analog compositions | Amgen Inc. |
| 2002364549 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc |
| 2002364503 | TUMOR ENDOTHELIAL MARKER 5 MOLECULES AND USES THEREOF | AMGEN INC. |
| 2003209058 | COMPOUNDS AND METHODS OF USES | AMGEN INC. |
| 2003208952 | Heterocyclic arylsulfonamidobenzyl compounds | Amgen Inc. |
| 2003210811 | Arylsulfonamidobenzyl compounds | Amgen Inc. |
| 2003215231 | Thiazolyl urea compounds for the treatment of cancer | AMGEN INC. |
| 2002365179 | Specific binding agents of human angiopoietin-2 | Amgen, Inc. |
| 2003224844 | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins | Amgen Inc. |
| 2003233671 | Calcium receptor modulating arylalkylamines | Amgen Inc. |
| 2003234628 | Substituted heterocyclic compounds and methods of use | Amgen Inc. |
| 2002367152 | IL-17 LIKE MOLECULES AND USES THEREOF | AMGEN INC. |
| 2003237235 | Calcium receptor modulating agents | Amgen, Inc. |
| 2003243139 | Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors | Amgen Inc. ; Medarex, Inc. |
| 2003245455 | HAMMERHEAD RIBOZYMES | AMGEN INC. |
| 2003245526 | Improved compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|--|--------------------------------------|
| 2003247425 | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain | Amgen Inc. |
| 2003252011 | Substituted 2-alkylamine nicotinic amide derivatives and use there of | Amgen Inc. |
| 2010330794 | Wise binding agents and epitopes | Amgen Inc. |
| 2010328444 | Human antigen binding proteins that bind beta-Klotho, FGF receptors and complexes thereof | Amgen Inc. |
| 2003256481 | Substituted anthranilic amide derivatives and methods of use | Amgen Inc. |
| 2003256577 | SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. |
| 2003256613 | PROTEIN CONJUGATES WITH A WATER-SOLUBLE BIOCOMPATIBLE, BIOGRADABLE POLYMER | AMGEN INC. |
| 2010321832 | Anti-Orai1 antigen binding proteins and uses thereof | Amgen Inc. |
| 2003261493 | Stem Cell Factor | Amgen Inc. |
| 2003262190 | HER-2 RECEPTOR TYROSINE KINASE MOLECULES AND USES THEREOF | AMGEN, INC. |
| 2003263784 | Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders | Amgen Inc. |
| 2003264047 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. |
| 2003270370 | THERAPEUTIC HUMAN ANTI-IL-1R1 MONOCLONAL ANTIBODY | AMGEN, INC. |
| 2003270701 | Antiinflammation agents | Amgen Inc. |
| 2003273295 | 1, 4, 5-substituted 1, 2-dihydro-pyrazol-3-one and 3-alkoxy-1H-pyrazole derivatives S TNF-alpha and interleukin lowering agents for the treatment of inflammations | Amgen Inc. |
| 2003273579 | 2-OXO-1,3,4-TRIHYDROQUINAZOLIN YL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. |
| 2003275137 | Peptides and related molecules that modulate nerve growth factor activity | Amgen Inc. |
| 2003278957 | MODULATION OF FORKHEAD BOX O1A EXPRESSION | AMGEN, INC. |
| 2004200516 | Methods of Increasing Lean Tissue Mass Using OB Protein Compositions | Amgen Inc. |
| 2003279258 | METHOD FOR TREATMENT OF INDWELLING CATHETER OCCLUSION USING FIBRINOLYTIC METALLOPROTEINASES | AMGEN INC. |
| 2004200687 | Modified peptides as therapeutic agents | Amgen Inc. |
| 2004200690 | Modified peptides as therapeutic agents | Amgen Inc. |
| 2004200691 | Modified peptides as therapeutic agents | Amgen Inc. |
| 2004200776 | Fibrinolytically active polypeptide | Amgen Inc. |
| 2004200797 | Carboxylic Acids and Carboxylic Acid Isosteres of N-Heterocyclic Compounds | GPI Nil Holdings, Inc. ; Amgen, Inc. |

| Number | Title | Owner |
|----------------------------|---|----------------------------|
| 2003285874 | HUMAN ANTI-IFN-Gamma NEUTRALIZING ANTIBODIES AS SELECTIVE IFN-Gamma PATHWAY INHIBITORS | AMGEN INC. |
| 2003286437 | Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors | Medarex, Inc. ; Amgen Inc. |
| 2003285160 | Fused heterocyclic compounds | Amgen, Inc. |
| 2004201326 | Dextran-Leptin Conjugates, Pharmaceutical Compositions and Related Methods | Amgen Inc. |
| 2004201574 | OB Protein Receptor and Related Compositions and Methods | Amgen Inc. |
| 2003298816 | Antibodies directed to Tumor Necrosis Factor and uses thereof | Amgen Fremont, Inc. |
| 2004201694 | Pharmaceutical compositions of fibrinolytic agent | Amgen Inc. |
| 2003297398 | Asthma and allergic inflammation modulators | Amgen Inc. |
| 2003301195 | Binding agents which inhibit myostatin | Amgen Inc. |
| 2003299970 | RNA interference | AMGEN INC. |
| 2003299971 | Combination therapy with co-stimulatory factors | AMGEN INC. |
| 2003299980 | 2-oxopyridin-3-yl thia (DI) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases | AMGEN INC. |
| 2003300395 | WNT-1 inhibitory factor-1 (WIF-1) molecules and uses thereof | AMGEN INC. |
| 2004202013 | Production of pluripotent granulocyte colony-stimulating factor | Kirin-Amgen, Inc. |
| 2004202101 | Canine OB Protein Compositions and Methods | Amgen Inc. |
| 2003301436 | Benzimidazole derivatives and their use as vanilloid receptor ligands | AMGEN INC. |
| 2004202431 | N-terminally chemically modified protein compositions and methods | Amgen Inc. |
| 2004202448 | OB Fusion Protein Compositions and Methods | Amgen Inc. |
| 2001270266 | Thymic stromal lymphopoietin receptor molecules and uses thereof | Amgen Inc. |
| 2004231208 | Modified peptides as therapeutic agents | Amgen Inc. |
| 2004233543 | GCSF Conjugates | Amgen Inc. |
| 2004235682 | N-Terminally chemically modified protein compositions and methods | Amgen Inc. |
| 2004242465 | Fibroblast Growth Factor-Like Polypeptides | Amgen Inc. |
| 2005200949 | Sustained-Release Delayed Gels | Amgen Inc. |
| 2005201491 | Interferon-Like Molecules and Uses Thereof | Amgen Inc. |
| 2001259432 | Modified peptides, comprising an FC domain, as therapeutic agents | Amgen Inc. |
| 2005201799 | Osteoprotegerin binding proteins and receptors | Amgen Inc. |
| 2001261557 | Methods and compositions of matter concerning april/g70, bcma, blys/aggp-3, and taci | Amgen Inc. |
| 2005202768 | Transgenic Mammals Having Human IG LOCI Including Plural Vh and Vk Regions and Antibodies Produced Therefrom | Amgen Fremont Inc. |
| 2001237041 | Kinase inhibitors | Amgen Inc. |
| 2004212490 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. |
| 2001241968 | Chordin-like-2 molecules and uses thereof | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|---|-------------------------------------|
| 2005209571 | Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/ AGP-3, and TACI | Amgen Inc. |
| 2001257173 | Apo-ai/aii peptide derivatives | Amgen Inc. |
| 2005209710 | Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof | Amgen Inc. |
| 2004223827 | Heterocyclic compounds and methods of use | Amgen Inc. |
| 2005211578 | Integrin/adhesion antagonists | Amgen Inc. |
| 2001284909 | Urea compounds and methods of uses | Amgen Inc. |
| 2004231070 | Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof | Amgen, Inc. ; Array BioPharma, Inc. |
| 2001245675 | G-protein coupled receptors | Amgen Inc. |
| 2004230938 | Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2 | Amgen Inc. |
| 2005232321 | Methods and compositions for treating IgE-related disease using NNT1-inhibitors | Amgen Inc. |
| 2005237128 | Compositions and Methods for the Prevention or Treatment of Cancer and Bone Loss Associated with Cancer | Amgen Inc. |
| 2001271618 | B7-like molecules and uses thereof | Amgen Inc. |
| 2004258862 | 2-amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of T cell activation for the treatment of inflammatory diseases | Amgen Inc. |
| 2001259029 | Il-17 receptor like molecules and uses thereof | Amgen Inc. |
| 2004303757 | Piperazine derivatives and methods of use | Amgen Inc. |
| 2004266228 | Melanin concentrating hormone receptor antagonists | Amgen, Inc. |
| 2004266233 | Melanin concentrating hormone receptor antagonist | Amgen, Inc. |
| 2004267030 | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors | Amgen, Inc. ; Medarex, Inc. |
| 2004261941 | Antagonists and agonists of LDCAM and methods of use | Amgen Inc. |
| 2004259737 | 2-aminopyrimidine and 2-aminopyridine-4-carbamates for use in the treatment of autoimmune diseases | Amgen Inc. |
| 2006200437 | Substituted alkylamine derivatives and methods of use | Amgen Inc. |
| 2004262014 | Crystalline tumor necrosis factor receptor 2 polypeptides | Amgen Inc. |
| 2004265595 | Specific binding agents to hepatocyte growth factor | Amgen Fremont Inc. ; Amgen Inc. |
| 2004261587 | Substituted pyridones and pyrimidinones with antiinflammatory properties | Amgen Inc. |
| 2004264354 | Arylsulfonamidobenzyl compounds | Amgen Inc. |
| 2004269000 | Substituted 2,3-dihydro-1H-isoindol-1-one derivatives and methods of use | Amgen Inc. |
| 2004269020 | Substituted isoquinoline derivatives and methods of use | Amgen Inc. |
| 2001250794 | Kcnb: a novel potassium channel protein | Amgen Inc. |
| 2006200638 | Pharmaceutical compositions of fibrinolytic agent | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|--|---|
| 2004259355 | Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor | Amgen Inc. |
| 2006200794 | Fhm, A novel member of the TNF ligand supergene family | Amgen Inc. |
| 2004261936 | Short interfering RNA as an antiviral agent for Hepatitis C | Amgen Inc |
| 2004267096 | Substituted pyrimidinone derivatives and methods of use | Amgen Inc. |
| 2012203221 | Human Antibodies Derived From Immunized Xenomice | Amgen Fremont Inc. |
| 2006200820 | Fibroblast Growth Factor-23 Molecules and Uses Thereof | Amgen Inc. |
| 2006200916 | Secreted Epithelial Colon Stromal-1 Polypeptides, Nucleic Acids Encoding the Same and Uses Thereof | Amgen Inc. |
| 2006200977 | Specific binding agents of human angiopoietin-2 | Amgen Inc. |
| 2006200981 | Specific binding agents of human angiopoietin-2 | Amgen Inc. |
| 2006200982 | Specific binding agents of human angiopoietin-2 | Amgen Inc. |
| 2004269034 | Substituted heterocyclic compounds and methods of use | Amgen Inc. |
| 2004279318 | Rapid dissolution formulation of a calcium receptor-active compound | Amgen Inc. |
| 2001255256 | Chemically modified novel erythropoietin stimulating protein compositions and methods | Amgen Inc. |
| 2004275700 | Antibodies to M-CSF | Warner-Lambert Company LLC ; Amgen Fremont Inc. |
| 2004278416 | Salts and polymorphs of a potent antidiabetic compound | Amgen, Inc. |
| 2004278382 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. |
| 2006201747 | Methods of Increasing Lean Tissue Mass Using OB Protein Compositions | Amgen Inc. |
| 2004285928 | Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction | Amgen, Inc. |
| 2004285467 | Antagonists of the bradykinin B1 receptor | Amgen Inc. |
| 2004285920 | Substituted heterocyclic compounds and methods of use | Amgen Inc. |
| 2004287431 | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent | Amgen Inc. |
| 2006202029 | Method for localized administration of fibrinolytic metalloproteinases | Amgen Inc. |
| 2004290016 | Monkey immunoglobulin sequences | Amgen Inc. |
| 2004286836 | Triazole compounds and uses related thereto | Amgen Inc. ; Japan Tobacco, Inc. |
| 2006202524 | B7-Like Molecules and Uses Thereof | Amgen, Inc. |
| 2006202629 | Chondromodulin-I Related Peptide | Amgen Inc. |
| 2004308908 | HEH4 molecules and uses thereof | Amgen Inc. |
| 2004308932 | Aryl sulfonamide compounds and uses related thereto | Amgen Inc |
| 2004309373 | Methods for identifying functional antibodies | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|--|----------------------------------|
| 2005206561 | bis-Bicyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain | Amgen Inc. |
| 2005209257 | Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain. | Amgen Inc. |
| 2005204678 | Antibodies to MAdCAM | Pfizer Inc. ; Amgen Fremont Inc. |
| 2006203429 | OPG Fusion Protein Compositions and Methods | Amgen Inc. |
| 2006203474 | ATP - Binding Cassette Transporter - Like Molecules and Uses Thereof | Amgen Inc. |
| 2006203546 | Transforming Growth FactorBeta-Related Molecules and Uses Thereof | Amgen Inc. |
| 2005206524 | Substituted diazabicycloheptanes and their use as protein kinase inhibitors | Amgen Inc. |
| 2005206571 | Compounds and methods of use | Amgen Inc. |
| 2005207946 | Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer | Amgen Inc. |
| 2005212517 | Pyrimidine derivatives for use as vanilloid receptor ligands and their use in the treatment of pain | Amgen Inc. |
| 2005206557 | Substituted heterocyclic compounds and methods of use | Amgen Inc. |
| 2005206562 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. |
| 2005212438 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. |
| 2005221140 | Therapeutic modulation of PPAR (gamma) activity | Amgen Inc. |
| 2004315196 | Process for purifying proteins | Amgen Inc. |
| 2005231822 | Methods of reducing aggregation of IL1ra | Amgen Inc. |
| 2002239806 | Antiinflammation agents | Amgen Inc. |
| 2005220728 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | Amgen Inc. |
| 2005229009 | Monoclonal antibodies specific for human OX40L (CD 134L) | Abgenix, Inc. ; Amgen, Inc. |
| 2005229001 | Chemically modified protein compositions and methods | Amgen Inc. |
| 2005237542 | Sustained release formulations | Amgen Inc. |
| 2006228063 | Use of IL-1 inhibitors and TNF antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia | Amgen Inc. |
| 2006228095 | Angiopoietin-2 specific binding agents | Amgen Inc. |
| 2005249381 | Antibodies of angiogenesis inhibiting domains of CD148 | Amgen, Inc. |
| 2005250341 | Antibodies to angiogenesis inhibiting domains of CD148 | Amgen Inc. |
| 2005228856 | Pyrazole compounds and uses related thereto | Amgen Inc. |
| 2005245386 | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer | Amgen Inc. |
| 2005243732 | Aryl sulfones and uses related thereto | Amgen, Inc. |
| 2005250336 | Arylsulfonamides and uses as hydroxysteroid dehydrogenase | Amgen, Inc. |
| 2005238511 | Low molecular weight polylactic acid polymers | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|--|---------------------------|
| 2005260031 | Condensed triazoles and indazoles useful in treating cytokines mediated diseases and other diseases | Amgen Inc. |
| 2001255516 | Methods and compositions for the prevention and treatment of anemia | Amgen Inc. |
| 2005247929 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | Amgen Inc. ; Biovitrum AB |
| 2005267161 | Substituted aryl-amine derivatives and methods of use | Amgen Inc. |
| 2005265150 | C-MET kinase binding proteins | Amgen Mountain View Inc. |
| 2007200149 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. |
| 2005275036 | 1,2,3,4-tetrahydropyrazin-2-yl acetamides and their use as bradykinin antagonists for the treatment of inflammation related disorders | Amgen Inc. |
| 2007200247 | G-CSF analog compositions | Amgen Inc. |
| 2005265319 | Therapeutic peptides | Amgen Inc. |
| 2005267065 | Method and apparatus for forming a dilution by fluid dispersion | Amgen Inc. |
| 2005266946 | Delivery of high cell mass in a syringe and related methods of cryopreserving cells | Amgen, Inc. |
| 2005260032 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity | Amgen Inc. |
| 2005260077 | Furanopyrimidines | Amgen Inc. |
| 2005267722 | Antibodies to Dkk-1 | Amgen Inc. |
| 2005269819 | Generic probes for the detection of phosphorylated sequences | Amgen Inc. |
| 2005260629 | Imidazolo-related compounds, compositions and methods for their use | Amgen SF, LLC |
| 2005260630 | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido(2,3-D)pyrimidin-4(3H)-one-related compounds, compositions and methods for their use | Amgen SF, LLC |
| 2005260620 | Fused pyrimidine derivatives and compositions thereof as CXCR3 receptor modulators, useful in prevention and treatment of inflammatory and immunoregulatory disorders and diseases | Amgen SF, LLC |
| 2001238680 | Antagonistic selective binding agents of osteoprotegerin binding protein | Amgen Inc. |
| 2007200628 | Cystine-Knot Polypeptides: Cloaked-2 Molecules and Uses Thereof | Amgen Inc. |
| 2007200662 | L-methionine as a stabilizer for NESP/ EPO in HSA-free formulations | Kirin-Amgen, Inc. |
| 2007200885 | IL-17 Receptor Like Molecules and Uses Thereof | Amgen Inc. |
| 2007200920 | B7 Related Protein-2 Molecules and Uses Thereof | Amgen Inc. |
| 2005272627 | Substituted benzofused heterocycles | Amgen Inc. |
| 2005272786 | Bisaryl-sulfonamides | Amgen Inc. |
| 2005284904 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. |
| 2005332339 | Furanopyridine derivatives as ACK1 and Lck modulators | Amgen Inc. |
| 2007201047 | CD20/IgE-Receptor Like Molecules and Uses Thereof | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|---|-----------------------------------|
| 2005289426 | Substituted heterocyclic compounds and methods of use | Amgen Inc. |
| 2005289685 | Modified Fc molecules | Amgen Inc. |
| 2007201478 | Stem Cell Factor | Amgen Inc. |
| 2005277236 | Methods and compositions for treating allergic inflammation | Amgen Inc. |
| 2005289881 | Substituted sulfonamidopropionamides and methods of use | Amgen Inc. |
| 2005294418 | Substituted sulfones and methods of use | Amgen Inc. |
| 2005295752 | Imidazole derivatives as vanilloid receptor ligands | Amgen Inc. |
| 2005299489 | Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament | Amgen Inc. |
| 2005295441 | Thiadiazole compounds and methods of use | Amgen, Inc. |
| 2005292152 | Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors | Amgen Inc |
| 2005295818 | Novel B1 bradykinin receptor antagonists | Amgen Inc. |
| 2005310305 | Methods for refolding polypeptides | Amgen Inc. |
| 2012203633 | IL-1 family variants | Amgen Inc. |
| 2001280733 | C3B/C4B complement receptor-like molecules and uses thereof | Amgen Inc. |
| 2005295940 | Triazoles and their use as bradykinin B1 receptor antagonists | Amgen Inc. |
| 2005299716 | Methods for refolding of recombinant antibodies | Amgen Inc. |
| 2006208226 | Humanized anti-amyloid antibody | Amgen Inc. |
| 2005295260 | Angiopoietin-2 specific binding agents | Amgen Inc. |
| 2005295414 | Heteroaryl-substituted alkyne compounds and method of use | Amgen Inc. |
| 2010319483 | Material and methods for treating or preventing HER-3 associated diseases | U3 Pharma GmbH ; Amgen |
| 2001288812 | TNF receptor-like molecules and uses thereof | Amgen Inc. |
| 2007201923 | Peptides and related compounds having thrombopoietic activity | Amgen Inc. |
| 2001247858 | Beta-like glycoprotein hormone polypeptide and heterodimer | Amgen Inc. |
| 2001257321 | Parathyroid hormone and parathyroid hormone-related protein antagonists | Amgen Inc. |
| 2001278188 | Tyrosine derivatives as phosphatase inhibitors | Amgen Inc. ; Array Biopharma Inc. |
| 2001279024 | C3b/C4b complement receptor-like molecules and uses thereof | Amgen Inc. |
| 2001272968 | Il-17 molecules and uses thereof | Amgen Inc. |
| 2005312048 | Quinolines and quinazoline analogs and their use as medicaments for treating cancer | Amgen Inc. |
| 2005319176 | Compositions comprising anti-IGF-1 receptor antibodies and methods for obtaining said antibodies | Amgen Inc. |
| 2007202616 | IL-17 Like Molecules and Uses Thereof | Amgen Inc. |
| 2007202619 | Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors | Amgen Inc. ; Medarex, Inc. |
| 2005316312 | Aminopyrimidine compounds and methods of use | Amgen, Inc. |

| Number | Title | Owner |
|----------------------------|--|---|
| 2005319137 | Substituted heterocyclic compounds and methods of use | Amgen Inc. |
| 2005322410 | Antibodies directed to GPNMB and uses thereof | CuraGen Corporation ; Amgen Fremont Inc. |
| 2005319404 | Binding proteins specific for human Matriptase | Dendreon Corporation ; Amgen Fremont Inc. |
| 2006206166 | Method of conjugating aminothiols containing molecules to vehicles | Amgen Inc. |
| 2006210848 | Compositions and methods for treating fibrotic disorders | Amgen Inc. |
| 2006216477 | Epidermal growth factor receptor mutations | Amgen Inc. |
| 2006218449 | Phthalazine, azaand diazaphthalazine compounds and methods of use | Amgen Inc. |
| 2006226897 | Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors | Amgen Inc. |
| 2006227429 | Methods of decreasing calcification | Amgen Inc. |
| 2006232378 | Epidermal growth factor receptor gene copy number | Amgen Inc. |
| 2006239216 | Substituted amide derivatives as protein kinase inhibitors | Amgen Inc. |
| 2006239928 | Toxin peptide therapeutic agents | Amgen Inc. |
| 2006241072 | Biodegradable peptide sustained release compositions containing porogens | Amgen Inc. |
| 2006236417 | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies | Amgen Fremont Inc. |
| 2006247487 | Antipyretic agents against VR1-antagonist-induced increases in body temperature | Amgen Inc. |
| 2006242431 | Sclerostin binding agents | UCB Pharma S.A. ; Amgen, Inc. |
| 2006242476 | Sclerostin epitopes | UCB Pharma S.A. ; Amgen, Inc. |
| 2006247039 | Compositions and methods for increasing the stability of antibodies | Amgen Inc. |
| 2006251768 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | Amgen Inc. |
| 2006239860 | Antibodies to myostatin | Amgen Fremont Inc. ; Pfizer Inc. |
| 2006259664 | Self-buffering protein formulations | Amgen Inc. |
| 2007240151 | Tumor Endothelial Marker 7Alpha Molecules and Uses Thereof | Amgen Inc. |
| 2002217969 | Polypeptides involved in immune response | Amgen Inc. ; Amgen Canada Inc. |
| 2006265835 | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer | Amgen Inc. |
| 2008200005 | Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom | Amgen Fremont Inc. |
| 2006261715 | Anti-inflammatory aryl nitrile compounds | Amgen Inc. |
| 2006259349 | Benzamide derivatives and uses related thereto | Amgen Inc. |
| 2006279717 | Modified Fc molecules | Amgen Inc. |
| 2012203443 | Methods and compositions for treating tumor diseases | Amgen Inc. |
| 2012203432 | Human Monoclonal Antibodies to Activin Receptor-like Kinase-1 | Amgen Fremont Inc. ; Pflizer Inc. |
| 2006279372 | Bis-aryl amide compounds and methods of use | Amgen Inc. |
| 2006272804 | Concentrated protein lyophilates, methods, and uses | Amgen Inc. |
| 2006270009 | Human anti-B7RP1 neutralizing antibodies | Amgen Inc. ; Medarex Inc. |

| Number | Title | Owner |
|----------------------------|--|--|
| 2006275475 | Formulations that inhibit protein aggregation | Amgen Inc. |
| 2006283592 | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators | Amgen Inc. |
| 2006295340 | Stable aqueous protein or antibody pharmaceutical formulations and their preparation | Amgen Inc. |
| 2006292433 | Method for generating F(ab') ₂ antibody fragments | Amgen Inc. |
| 2006279548 | Phosphodiesterase 10 inhibitors | Memory Pharmaceuticals Corporation ; Amgen, Inc. |
| 2006272922 | Aniline sulfonamide derivatives and their uses | Amgen Inc. |
| 2006283476 | Bis-aryl urea compounds for the treatment of protein kinase-mediated diseases | Amgen Inc. |
| 2006285080 | Methods of modulating intestinal fluid balance | Hebert, P. ; Amgen Inc. ; Geibel, J. |
| 2006291234 | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders | Amgen Inc. |
| 2008201194 | Peptides and related molecules that modulate nerve growth factor activity | Amgen Inc. |
| 2006284884 | Trail receptor 2 polypeptides and antibodies | Amgen Inc. |
| 2006297571 | Human monoclonal antibodies to activin receptor-like kinase-1 | Amgen Fremont Inc. ; Pfizer Inc. |
| 2006304778 | Methods of decreasing vascular calcification using IL-1 inhibitors | Amgen Inc. |
| 2006304835 | CGRP peptide antagonists and conjugates | Amgen Inc. |
| 2006304879 | Pyrrolo-pyridine derivatives for the treatment of cancer diseases | Amgen Inc. |
| 2008201780 | Fibroblast growth factor-like polypeptides | Amgen Inc. |
| 2006304846 | Methods for generating monovalent IgG | Amgen Inc. |
| 2006316620 | Beta-secretase modulators and methods of use | Amgen Inc. |
| 2006318643 | Beta-secretase modulators and methods of use | Amgen Inc. |
| 2006318640 | Beta-secretase modulators and methods of use | Amgen Inc. |
| 2006322028 | Improved host cells and culture methods | Amgen Inc. |
| 2008202257 | Benzimidazole derivatives and their use as vanilloid receptor ligands | Amgen Inc. |
| 2006315542 | RANKL antibody-PTH/PTHrP chimeric molecules | Amgen Inc. |
| 2006324163 | Improved production of glycoproteins using manganese | Amgen Inc. |
| 2006329963 | Polishing steps used in multi-step protein purification processes | Amgen Inc. |
| 2007204987 | Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents | Amgen Inc. |
| 2006308614 | Novel activin receptor and uses thereof | Amgen Inc. |
| 2008202516 | Osteoprotegerin binding proteins and receptors | Amgen Inc. |
| 2008202517 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. |
| 2006316867 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | Amgen Inc. ; Biovitrum AB |
| 2006336563 | Solid-state form of AMG 706 and pharmaceutical compositions thereof | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|---|---|
| 2006317070 | Catalyzed process of making C5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | Amgen, Inc. |
| 2006326662 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | Amgen Inc. |
| 2006332065 | Antibodies directed to HER-3 and uses thereof | Amgen Inc. ; U3 Pharma GmbH |
| 2008202860 | Human Antibodies Derived From Immunized Xenomice | Amgen Fremont Inc. |
| 2008202912 | Transgenic Animals for Producing Specific Isotypes of Human Antibodies Via Non-Cognate Switch Regions | Amgen Fremont Inc. |
| 2006321906 | Uses of myostatin antagonists | Amgen Inc. |
| 2006326540 | Diaza heterocyclic sulfonamide derivatives and their uses | Amgen Inc. |
| 2006330888 | Nitrogencontaining bicyclic hetroaryl compounds for the treatment of Raf protein kinase-mediated diseases | Amgen Inc. |
| 2007208226 | Thrombopoietic compounds | Amgen Inc. |
| 2006321919 | Bradykinin 1 receptor antagonists | Amgen Inc. |
| 2007208274 | Methods for modulating mannose content of recombinant proteins | Amgen Inc. |
| 2007207743 | Thiazole compounds as protein kinase B (PKB) inhibitors | Amgen Inc. |
| 2007208351 | Aurora kinase modulators and method of use | Amgen Inc. |
| 2007210234 | Ang2 and VEGF inhibitor combinations | Amgen Inc. |
| 2007212696 | Hydrate forms of AMG706 | Amgen Inc. |
| 2008207483 | Therapeutic Human Anti-IL-1R Monoclonal Antibody | Medarex, Inc. ; Amgen Inc. |
| 2007212195 | Antibodies that bind PAR-2 | Amgen Inc. |
| 2007221294 | Multi-cyclic compounds and method of use | Amgen Inc. |
| 2007217750 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | Amgen Inc. ; Memory Pharmaceuticals Corporation |
| 2007217474 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | Memory Pharmaceuticals Corporation ; Amgen Inc. |
| 2007221049 | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors | Memory Pharmaceuticals Corporation ; Amgen Inc. |
| 2007225208 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | Amgen Inc. |
| 2007223801 | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors | Amgen Inc. ; Memory Pharmaceuticals Corporation |
| 2007223985 | Quinazoline derivatives as phosphodiesterase 10 inhibitors | Amgen Inc. ; Memory Pharmaceuticals Corporation |
| 2007224094 | Phosphodiesterase 10 inhibitors | Amgen Inc. ; Memory Pharmaceuticals Corporation |
| 2007238705 | Agonist erythropoietin receptor antibodies | Amgen Inc. |
| 2008229797 | Methods of treatment using specific binding agents of human angiopoietin-2 | Amgen Inc. |
| 2007240568 | Thieno-[2,3-d]pyrimidine and thienopyridazine compounds and methods of use | Amgen Inc. |
| 2007243318 | Humanized c-Kit antibody | Amgen Inc. |
| 2007238704 | Erythropoietin receptor agonists | Amgen Inc. |
| 2007240313 | GLP-1 compounds | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|--|---|
| 2007240656 | Lyophilized therapeutic peptibody formulations | Amgen Inc. |
| 2007230724 | Methods and compositions for making and using polymorphs of cinacalcet | Amgen Inc. |
| 2007231594 | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxysteroid dehydrogenases | Amgen Inc. |
| 2007227251 | Antibodies directed to angiopoietin-like protein 4 and uses thereof | CuraGen Corporation ; Amgen Fremont, Inc. |
| 2006341443 | Substituted heterocyclic compounds and methods of use | Amgen Inc |
| 2007240317 | Stable emulsion formulations | Amgen Inc. |
| 2008243261 | Arylsulfonamidobenzyl compounds | Amgen Inc. |
| 2007240315 | GLP-1 compound/glucagon antibody compositions | Amgen Inc. |
| 2007320075 | Antibodies to SARS coronavirus | Amgen Inc. |
| 2007240727 | Immunoglobulin constant region domains with enhanced stability | Amgen, Inc. |
| 2007240732 | Buffering agents for biopharmaceutical formulations | Amgen, Inc. |
| 2007259143 | Benzamide derivatives and uses related thereto | Amgen Inc. |
| 2007259144 | Benzamide derivatives as modulators of 11beta-HSD1 for treating diabetes and obesity | Amgen Inc. |
| 2007265475 | Methods for treating atherosclerosis | Amgen Inc. |
| 2007275638 | Method of detecting and/ or measuring hepcidin in a sample | Amgen Inc. |
| 2008261137 | Antibodies to OPGL | Amgen Fremont Inc.; Amgen Inc. |
| 2007261362 | Thrombopoietic compounds | Amgen Inc. |
| 2007275696 | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors | Amgen Inc. |
| 2007272783 | Fused heterocyclic derivatives and methods of use | Amgen Inc. |
| 2007272830 | Alkyne-substituted pyridone compounds and methods of use | Amgen Inc. |
| 2007265467 | Glycine transporter-1 inhibitors | Amgen Inc. |
| 2007271918 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | Amgen Inc. ; Galapagos SAS |
| 2007275301 | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 | Amgen Inc. ; Biovitrum AB |
| 2007275653 | Benzo(d) isoxazole derivatives as c-kit tyrosine kinase inhibitors for the treatment of disorders associated with the over production of histamine | Amgen Inc. |
| 2007275682 | Substituted pyridone compounds and methods of use | Amgen Inc. |
| 2007275683 | Di-amino-substituted heterocyclic compounds and methods of use | Amgen Inc. |
| 2007293065 | Phthalazine, AZA and diazaphthalazine compounds and methods of use | Tasker, A. ; Zhang, D. ; Amgen Inc. |
| 2007292816 | Benzo-fused compounds for use in treating metabolic disorders | Amgen Inc. |
| 2007293028 | Heterocyclic GPR40 modulators | Amgen Inc. |
| 2007294909 | IL-1 family variants | Amgen Inc. |
| 2007288202 | Sorbic acid analog co-crystals | Amgen Inc. |
| 2007294580 | Anti-activin A antibodies and uses thereof | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|--|------------|
| 2007297652 | Compositions and methods relating to glucagon receptor antibodies | Amgen Inc. |
| 2007307031 | Imidazoand triazolo-pyridine compounds and methods of use thereof | Amgen Inc. |
| 2007314519 | IL-17 receptor A antigen binding proteins | Amgen Inc. |
| 2007309616 | Stable polypeptide formulations | Amgen Inc. |
| 2007307107 | Stable antibody formulations | Amgen Inc. |
| 2007318092 | Calcium receptor modulating agents | Amgen Inc. |
| 2010257339 | Compositions and methods relating to anti-IGF-1 receptor antibodies | Amgen Inc. |
| 2007308154 | N-aryl pyrazole compounds for use against diabetes | Amgen Inc. |
| 2007334321 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | Amgen Inc. |
| 2007338792 | Substituted heterocycles and methods of use | Amgen Inc. |
| 2007338795 | Substituted heterocycles and methods of use | Amgen Inc. |
| 2007343796 | Toxin peptide therapeutic agents | Amgen Inc. |
| 2009202513 | Specific binding agents of human angi- opoietin-2 | Amgen Inc. |
| 2007343726 | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases | Amgen Inc. |
| 2007338791 | Stable buffered formulations containing polypeptides | Amgen Inc. |
| 2007334323 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | Amgen Inc. |
| 2007338793 | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer | Amgen Inc. |
| 2008205252 | Bis-aryl amide derivatives useful for the treatment of cancer | Amgen Inc. |
| 2008214386 | Hepcidin and hepcidin antibodies | Amgen Inc. |
| 2008219166 | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors | Amgen Inc. |
| 2008223541 | Methods and compositions for treating tumor diseases | Amgen Inc. |
| 2008223338 | Variant activin receptor polypeptides and uses thereof | Amgen Inc. |
| 2008231384 | Heterocyclic compounds and their use | Amgen Inc. |
| 2008231385 | Delta3substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors | Amgen Inc. |
| 2008226803 | K-ras mutations and anti-EGFr antibody therapy | Amgen Inc. |
| 2008226808 | K-ras and B-raf mutations and antiEGFr antibody therapy | Amgen Inc. |
| 2008233088 | Calcimimetic compounds for use in the treatment of bowel disorders | Amgen Inc. |
| 2008231304 | Heterocyclic compounds and their uses | Amgen Inc. |
| 2008236670 | Aurora kinase modulators and method of use | Amgen Inc. |
| 2008241490 | Substituted biphenyl phenoxy-, thiophenyl and aminophenylpropanoic acid GPR40 modulators | Amgen Inc. |
| 2008241577 | Indanone derivatives that inhibit prolyl hydroxylase | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|---|--|
| 2008241483 | Quinolones and azaquinolones that inhibit prolyl hydroxylase | Amgen Inc. |
| 2008248165 | Diazaquinolones that inhibit prolyl hydroxylase activity | Amgen Inc. |
| 2008248201 | Compounds as CRTH2 and/or PGD2 receptors modulators and their use for treating asthma and allergic inflammation | Amgen Inc. |
| 2008248234 | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity | Amgen Inc. |
| 2008248073 | Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use | Amgen Inc. |
| 2008248296 | Pyrazolo-pyridinone and pyrazolopyrazinone compounds as P38 modulators, process for their preparation, and their pharmaceutical use | Amgen Inc. |
| 2008242665 | Identification and method for using the Pre-Ligand Assembly Domain of the IL17 receptor | Amgen Inc. ; The Research Foundation of State University of New York |
| 2008257145 | Substituted hydroxyethyl amine compounds as Beta-secretase modulators and methods of use | Amgen Inc. |
| 2008236765 | Anti-IgE antibodies | Pfizer Inc. ; Amgen Fremont Inc. |
| 2008262490 | Compositions and methods for producing bioactive fusion proteins | Amgen Inc. |
| 2008266948 | IL-17 heteromeric receptor complex | Amgen Inc. |
| 2008251405 | Improved feed media | Amgen Inc. |
| 2008262310 | Heterocyclic compounds as Raf kinase modulators | Amgen Inc. |
| 2008267017 | Tricyclic inhibitors of hydroxysteroid dehydrogenases | Amgen Inc. |
| 2008269181 | Methods of synthesizing cinacalcet and salts thereof | Amgen Inc. |
| 2008269199 | Process for making substituted 2-amino-thiazolones | Amgen Inc. |
| 2009245850 | Antibodies to DKK-1 | Amgen Inc. |
| 2008269128 | Phthalazine compounds, compositions and methods of use | Amgen Inc. |
| 2008271073 | Antigen binding proteins that bind PAR2 | Amgen Inc. |
| 2008279127 | IL-18 receptor antigen binding proteins | Amgen, Inc. |
| 2008276521 | Heterocyclic modulators of PKB | Amgen Inc. |
| 2008266131 | Methods of treating cell culture media for use in a bioreactor | Amgen Inc. |
| 2008269086 | Compositions of specific binding agents to hepatocyte growth factor | Amgen Inc. |
| 2008275595 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | Amgen Inc. |
| 2010200229 | Antibodies to angiogenesis inhibiting domains of CD148 | Amgen Inc. |
| 2008272762 | Measurement of protein using inclusion body dry weight | Amgen Inc. |
| 2008276512 | Thiadiazole modulators of (PKB) | Amgen Inc. |
| 2008282728 | PI3 kinase modulators and methods of use | Amgen Inc. |
| 2008279065 | Modified lecithin-cholesterol acyltransferase enzymes | Amgen Inc. |
| 2008289225 | Formulations of antibodies and Fc fusion molecules using polycations | Amgen Inc. |
| 2008288974 | Human c-fms antigen binding proteins | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|---|---|
| 2008293425 | Solid-state protein formulation | Amgen Inc. |
| 2008300019 | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling | Amgen Inc. |
| 2008298904 | Homogeneous antibody populations | Amgen Inc. |
| 2008288791 | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) | Amgen Inc. |
| 2008302313 | Method for inhibiting bone resorption | Amgen Inc. |
| 2008302746 | 1-(4-(benzylbenzamid0)-benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SIP receptor modulators for the treatment of immune disorders | Epix Pharmaceuticals, Inc. ; Amgen Inc. |
| 2008300028 | Antigen binding proteins capable of binding thymic stromal lymphopoietin | Amgen Inc. |
| 2008304111 | Pharmaceutical formulations | Amgen Inc. |
| 2008302747 | Human GM-CSF antigen binding proteins | Amgen Inc. |
| 2008307482 | Increasing erythropoietin using nucleic acids hybridizable to micro-RNA and precursors thereof | Amgen Inc. |
| 2008311974 | Calcium receptor modulating agents | Amgen Inc. |
| 2008311355 | Substituted biphenyl GPR40 modulators | Amgen Inc. |
| 2010201389 | Binding agents which inhibit myostatin | Amgen Inc. |
| 2010201600 | L-methionine as a stabilizer for NESP/ EPO in HSA-free formulations | Kirin-Amgen, Inc. |
| 2008319366 | Benzomorpholine derivatives and methods of use | Amgen Inc. |
| 2010201800 | Modified FC Molecules | Amgen Inc. |
| 2008303796 | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins | Amgen Inc. ; U3 Pharma GmbH |
| 2008330125 | Wise binding antibodies and epitopes | Amgen Inc. |
| 2008338464 | Method for treating bone fracture with anti-sclerostin antibodies | Amgen Inc. |
| 2010202177 | Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors | Medarex, Inc. ; Amgen Inc. |
| 2008335709 | Gamma secretase modulators | Amgen Inc. |
| 2008335788 | Glycine transporter-1 inhibitors | Amgen Inc. |
| 2008343924 | Phenyl acetic acid derivatives as inflammation modulators | Amgen Inc. |
| 2008343932 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | Amgen Inc. |
| 2008343855 | Anti-amyloid antibodies and uses thereof | Amgen Inc. |
| 2009204501 | Method for making antibody Fcheterodimeric molecules using electrostatic steering effects | Amgen Inc. |
| 2008343813 | Inhibitors of PI3 kinase | Amgen Inc. |
| 2008348182 | Fused heterocyclic derivatives and methods of use as c-Met inhibitors | Amgen Inc. |
| 2009206306 | Ferroportin antibodies and methods of use | Amgen Inc. |
| 2009244878 | IL-17RA-IL-17RB antagonists and uses thereof | Amgen Inc |
| 2009210741 | Stabilized protein compositions | Amgen Inc. |
| 2009215804 | Antibodies directed to angiopoietin-1 and angiopoietin-2 and use thereof | Amgen Inc. |
| 2009223851 | Methods of treating hyperacidic disorders | Geibel, J. ; Amgen Inc. |
| 2010214673 | Uses of myostatin antagonists | Amgen Inc. |

| Number | Title | Owner |
|----------------------------|---|--|
| 2010214691 | Uses of myostatin antagonists | Amgen Inc. |
| 2009220163 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | Amgen Inc. |
| 2009226024 | Aurora kinase modulators and method of use | Amgen Inc. |
| 2010219370 | IL-17 receptor A antigen binding proteins | Amgen Inc. |
| 2009228069 | Calcimimetic compound for use in the treatment of epithelial injury | Yale University ; Amgen Inc. |
| 2009233951 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | Amgen Inc. |
| 2009238550 | Neutralizing proprotein convertase subtilisin kexin type 9 (PCSK9) variants and uses thereof | Amgen Inc. |
| 2010227016 | Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof | CuraGen Corporation ; Amgen Fremont Inc. |
| 2010321720 | Monomeric antibody Fc | Amgen Inc. |
| 2009246946 | Anti-hepcidin antibodies and methods of use | Amgen Inc. |
| 2010241280 | Aurora kinase modulators and method of use | Amgen Inc. |
| 2009244504 | Urea compounds as gamma secretase modulators | Amgen Inc. |
| 2009246263 | Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer | Amgen Inc. |
| 2009248839 | Heterocycles as protein kinase inhibitors | Amgen Inc. |
| 2010241462 | Epidermal Growth Factor Receptor Mutations | Amgen Inc. |
| 2009256232 | FGF21 mutants and uses thereof | Amgen Inc. |
| 2009260447 | Inhibitors of PI3 kinase | Amgen Inc. |

Terms and Conditions

General

The information provided in this report is not in the nature of legal or other professional advice.

The information provided in this report is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals regarding any information in this report.

Patents, patent applications, trademarks and trademark applications shown as lapsed or ceased may be restored at a later date.

Disclaimer of warranty and limitation of liability

Neither IPMonitor, its affiliates nor any of their respective employees, agents, third party content providers or licensors warrant that the information contained in this report is error free; nor do they make any warranty as to the accuracy, reliability or content of any information in this report.

This report is provided on an "as is" basis; to the maximum extent permitted by law, IPMonitor disclaims all representations and warranties, express or implied, with respect to any information contained in this report. In addition, IPMonitor does not represent or warrant that the information contained in this report is accurate, complete or current.

This disclaimer of liability applies to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action.

Copyright

The content of this report may be protected by copyright laws and treaties around the world and all rights relating to the same are reserved. Any paper or digital copies of this report are not to be modified or any illustrations or any graphics used separately from any accompanying text.

Arbitration

Any dispute or difference whatsoever arising out of or in connection with this report shall be submitted to arbitration in accordance with, and subject to, The Institute of Arbitrators & Mediators Australia Rules for the Conduct of Commercial Arbitrations.

IPMonitor reserves the right to update the Terms and Conditions at any time without notice. Please see the full Terms and Conditions at www.IPMonitor.com.au/trademarks/info/terms